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Abstract
Studies from our lab have shown that decreasing myocardial G protein–coupled receptor kinase 2 (GRK2) activity and
expression can prevent heart failure progression after myocardial infarction. Since GRK2 appears to also act as a pro-death
kinase in myocytes, we investigated the effect of cardiomyocyte-specific GRK2 ablation on the acute response to cardiac
ischemia/reperfusion (I/R) injury. To do this we utilized two independent lines of GRK2 knockout (KO) mice where the GRK2
gene was deleted in only cardiomyocytes either constitutively at birth or in an inducible manner that occurred in adult mice
prior to I/R. These GRK2 KO mice and appropriate control mice were subjected to a sham procedure or 30 min of myocardial
ischemia via coronary artery ligation followed by 24 hrs reperfusion. Echocardiography and hemodynamic measurements
showed significantly improved post-I/R cardiac function in both GRK2 KO lines, which correlated with smaller infarct sizes in
GRK2 KO mice compared to controls. Moreover, there was significantly less TUNEL positive myocytes, less caspase-3, and -9
but not caspase-8 activities in GRK2 KO mice compared to control mice after I/R injury. Of note, we found that lowering
cardiac GRK2 expression was associated with significantly lower cytosolic cytochrome C levels in both lines of GRK2 KO mice
after I/R compared to corresponding control animals. Mechanistically, the anti-apoptotic effects of lowering GRK2
expression were accompanied by increased levels of Bcl-2, Bcl-xl, and increased activation of Akt after I/R injury. These
findings were reproduced in vitro in cultured cardiomyocytes and GRK2 mRNA silencing. Therefore, lowering GRK2
expression in cardiomyocytes limits I/R-induced injury and improves post-ischemia recovery by decreasing myocyte
apoptosis at least partially via Akt/Bcl-2 mediated mitochondrial protection and implicates mitochondrial-dependent
actions, solidifying GRK2 as a pro-death kinase in the heart.
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Introduction
The myocyte death that follows acute myocardial ischemia and
subsequent reperfusion (I/R) injury is a major factor contributing
to high mortality and morbidity in ischemic heart disease. Death
of myocytes after I/R injury can be due to autophagy, necrosis, or
apoptosis [1]. Apoptotic cell death is primarily orchestrated by
caspases, a group of aspartate-specific cysteine proteases which
reside in the cytosol as inactive proforms in healthy cells [2,3]. The
activation of caspases is controlled by two distinct pathways: the
death receptor (extrinsic) pathway and the mitochondrial (intrinsic)
pathway [4,5]. The ‘‘extrinsic’’ pathway is triggered by the binding
of ligands, such as tumor necrosis factor and Fas, to their cognate
receptors to induce receptor clustering and the formation of a
death-inducing signaling complex (DISC) [6,7]. This complex
recruits multiple procaspase-8 molecules via an adaptor molecule
FADD (Fas-associated death domain protein), resulting in the
activation of caspase-8 and downstream caspase-3 [6]. The
‘‘intrinsic’’ pathway utilizes mitochondria to produce cell death
through opening of the mitochondrial permeability transition pore
(mPTP), triggering the sudden release of cytochrome C and other
proteins from the intermembrane space of mitochondria into the
cytosol [8]. Released cytochrome C facilitates formation of the
‘‘apoptosome’’ complex, which results in caspase-9 activation and
subsequent activation of caspase-3, the final effector of apoptosis
[5,9].
In myocytes, the ‘‘intrinsic’’ pathway is activated by a variety of
cellular stimuli such as oxidative stress and hypoxia, which occurs
after ischemic injury [10,11]. Several studies have shown that
following I/R, cardiomyocyte apoptosis is controlled, at least in
part, by Bcl-2 family members [1,12]. Among the Bcl-2 family,
Bcl-xL and Bcl-2 are known to be anti-apoptotic, whereas Bax,
Bak, and Bad are pro-apoptotic [1,13,14]. Bad, through its Bcl-2
homology-3 domain, mediates its death-promoting activity
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through the binding of Bcl-xL. However, phosphorylation of Bad
by pro-survival kinases, such as Akt, leads to the release of both
Bcl-xL and Bcl-2 [15,16]. Phosphorylation of Bax retains it in the
cytoplasm and prevents translocation to mitochondria [17–19].
G protein–coupled receptor (GPCR) kinase 2 (GRK2), a critical
regulator of cardiac GPCRs such as b-adrenergic receptors (bARs)
has been also shown to be a key regulator of cardiac regulation
and contractile function [20]. GRK2 is up- regulated in both acute
and chronic heart failure (HF) [21,22]. In fact, studies have shown
that after myocardial ischemic injury, GRK2 up-regulation is an
early event and is ultimately responsible for crippling the
myocardial bAR system [23]. Recent studies from our lab have
shown that silencing myocardial GRK2 expression [22] or
preventing GRK2 activity (with a peptide inhibitor) [24] can
prevent or rescue HF progression after myocardial infarction.
Further, we have recently shown that when GRK2 expression is
increased in the heart, as seen with cardiac stress, significantly
more severe ischemic injury is seen after I/R injury [25]. The
mechanism by which GRK2 promotes cell death in the heart is
not fully understood as it appears to be associated with increased
apoptosis due to reduced activation of the Akt and subsequent
nitric oxide production [25].
In the present study, we investigated the direct role of GRK2 in
the regulation of myocardial apoptosis by using cardiac-specific
GRK2 knockout (KO) mice and an in vivo I/R injury model.
Importantly, we not only confirmed our previous findings that
GRK2 activity is associated with pro-death signaling after stress
that can negatively impact post-I/R function, we uncovered novel
information concerning potential signaling mechanisms including
implications for mitochondrial-dependent effects. These data
support inhibition of GRK2 as a therapeutic strategy for
cardioprotection.
Methods
Experimental Animals
Mice bearing floxed GRK2 alleles (GRK2 fl/fl) along with
cardiac-specific transgenic mice harboring Cre recombinase either
constitutively via the a-myosin heavy chain (aMHC) promoter or
tamoxifin (Tmx)-inducible via Cre fused to mutant estrogen
receptors (MerCreMer, MCM) have been previously described
and utilized by our laboratory [22,26,27]. GRK2fl/fl mice were
bred with these Cre Transgenic mice and resultant mice were
defined as GRK2KO (constitutive) or GRK2iKO (inducible)
mice. These mice were used for all experiments along with
appropriate control, wild-type (WT) mice (including GRK2 fl/fl
and MMC mice). All mice were in the C57/B6 genetic
background and all animal procedures and experiments were
carried out according to National Institutes of Health Guidelines
on the Use of Laboratory Animals and approved by the Animal
Figure 1. Cardiac GRK2 Expression in Knockout Mice. (A) Whole heart GRK2 expression from MerCreMer (MCM), GRK2fl/fl (GRK2f/f) and
GRK2iKO (inducible KO) groups before and after the treatment with tamoxifen. * p,0.05 vs. GRK2f/f, MCM and GRK2iKO treated with vehicle groups.
(B) GRK2 expression in cardiomyocytes isolated from GRK2iKO and GRK2f/f control mice. ** p,0.05 vs. GRK2f/f. (C) Whole heart GRK2 expression from
constitutive GRK2KO mice and GRK2fl/fl control mice. ** p,0.01 vs. GRK2f/f.
doi:10.1371/journal.pone.0066234.g001
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Care and Use Committee of Thomas Jefferson University and
Temple University.
Experimental Groups and Protocol
GRK2KO, GRK2iKO along with appropriate and WT control
mice were subjected to either a sham procedure or 30 min
myocardial ischemia via coronary artery ligation followed by
reperfusion to induce I/R injury as described [28]. At 24 hrs post-
I/R, cardiac function (using both echocardiography and hemo-
dynamics) and infarct size were measured. For signaling studies,
hearts were harvested at either 15 min post-I/R for preparation of
cardiac protein lysates and subsequent analysis as described in the
next section. For measurements of cytosolic cytochrome c and
BcL-2 proteins (Bad, Bcl-2 and Bcl-xL), 30 min of reperfusion was
utilized. Finally, at 3 hrs post-I/R another set of hearts were used
for TUNEL staining and caspases-3, -8, and -9 activities for
assessment of apoptosis.
Materials
Antibodies that recognize the either the phosphorylated or non-
phosphorylated forms of Akt (Ser473) were purchased from Cell
Signaling Technology (Beverly, MA). Antibodies against and Bad,
Bcl-2 (sc-7382), Bcl-xL were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). All other chemicals were
purchased from Sigma (St. Louis, MO).
In vivo Cardiac Functional Measurements
We assessed in vivo cardiac function following 24 hrs post-I/R
via either echocardiographic measurements (Vevo 770, VisualSo-
nics, Toronto, Canada) or hemodynamic measurements using left
ventricular (LV) catheterization (Millar Instruments, Houston,
TX) as previously reported [28].
Determination of LV Infarct Size and Ischemia Area
Myocardial infarct size was determined by Evans blue/TTC
double staining as described previously [28,29].
Determination of Myocardial Apoptosis
Myocardial apoptosis was determined by TUNEL staining and
caspase-3, -8 and -9 activity assays as described previously [29,30].
Quantification of Cytochrome C Release
Mitochondrial cytochrome C release was determined as
described with some modifications [11,31]. In brief, 25 mg of
myocardial tissue was minced on ice, resuspended in 500 ml of
MSH buffer (210 mM mannitol/70 mM sucrose/5 mM HEPES,
pH 7.5) supplemented with 1 mM EDTA, and homogenized with
a glass dounce homogenizer and teflon pestle. Cytosolic and
mitochondrial fractions were separated by differential centrifuga-
tion (5 min at 1000 g, 30 min at 17,530 g). The mitochondrial
pellet was resuspended in MSH buffer, sonicated for 20 s on ice,
and centrifuged at 17,530 g for 30 min at 4uC. The resulting
supernatant containing mitochondrial extract from this last
centrifuge or cytosolic extract from the first centrifugation
(5 min at 1000 g) were separately mixed with Laemmli’s loading
buffer, boiled for 5 min, and subjected to SDS/PAGE followed by
electroblotting to nitrocellulose. Western blotting for cytochrome
C and GAPDH were carried out by standard methods. Results
were expressed as the measured cytochrome C level normalized to
GAPDH levels as a loading control.
Neonatal Rat Ventricular Myocytes (NRVM) Isolation and
in vitro Models of Oxidative Stress
NRVMs from 1–2 day old rats were isolated as previously
described [25] and GRK2 expression was knocked down using
anti-GRK2 small interfering (si)RNA (12 nmol together with
HiPerfect Transfection Reagent (Qiagen, Valencia, CA), sense:
GCUCAGUUUCAUCCUGGAUtt, antisense: AUCCAGGAU-
GAAACUGAGCtt). Scrambled siRNA was used as control. After
72 hrs NRVMs were treated with chelerythrine (Chele, 10 mM)
for 30 min to induce oxidative stress as described previously
[32,33]. Whole cell lysates were prepared and subjected to
Figure 2. Loss of Cardiac GRK2 Expression Improves Post-I/R Cardiac Function. (A) Representative M-mode echocardiography recordings
from Sham control mice (S, n = 8) and 24 hr post-I/R mice from different groups (MCM, n = 10, GRK2fl/fl, n = 7, GRK2iKO, n = 14, and GRK2KO, n = 9).
(B-E) Mean6SEM of measured values from these groups of mice for LV internal diastolic dimension (LVIDd), (B); D, LV ejection fraction (LV EF%), (C);
LV fractional shortening (LV FS%), (D); and heart rate (HR), (E). * p,0.05 vs. MerCreMer (MCM) or GRK2fl/fl control groups.
doi:10.1371/journal.pone.0066234.g002
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immunoblotting to measure levels of GRK2, cleaved caspase-3,
Akt, Bcl-2, Bcl-xL and GAPDH.
Statistical Analysis
All values in the text and figures are presented as mean 6 SEM
of independent experiments from given n-sizes. Statistical signif-
icance was determined by one-way or two-way ANOVA followed
by the Bonferroni post-hoc test when appropriate. Probabilities of
0.05 or less were considered to be statistically significant.
Results
Lowering Cardiomyocyte GRK2 Levels Improves Post-I/R
Functional Recovery
Studies targeting the role of GRK2 in I/R injury were
performed with two independent lines of cardiac-specific GRK2
KO mice: a constitutive GRK2KO line and an inducible GRK2
KO line (termed GRK2iKO) where GRK2 was deleted in
adulthood using Tmx. As shown in Fig. 1, significant ($50%) but
not complete deletion of GRK2 in mouse hearts and cardiomy-
ocytes was observed in either line, which is consistent with our
previous report [22,27]. To investigate the impact of lowered
cardiomyocyte GRK2 levels on ischemic injury, we first measured
in vivo cardiac function using echocardiography and terminal
hemodynamics at 24 hrs post-I/R in both lines of GRK2 KO
mice along with their respective controls (MCM for GRK2iKO
and GRK2fl/fl for GRK2KO). As shown in Fig. 2, both lines of
control mice exhibited impaired anterior wall motion post-I/R
when compared to sham groups that was significantly improved in
GRK2KO and GRK2iKO mice. Of note, sham animals from
each line were initially used and since cardiac function was similar
amongst them we subsequently combined them into a single sham
control group. Specifically, MCM and GRK2fl/fl mice after I/R
had significantly increased left ventricle (LV) diastolic (LVIDd)
chamber dimensions and accordingly, decreased LV ejection
fraction (LVEF) and fractional shortening (LVFS) compared to
Sham controls (Fig. 2B–E). However, GRK2 lowering in myocytes
led to significantly smaller dimensions and improved function, a
result that indicates lower GRK2 levels can improve acute cardiac
function post I/R (Fig. 2).
Both constitutive and inducible GRK2 KO lines showed similar
improvement that was also found in hemodynamic measurements
where inotropic reserve was significantly improved in GRK2 KO
mice compared to corresponding control mice post-I/R (Fig. 3).
Parameters were studied both at baseline and in response to the
bAR agonist isoproterenol and included peak LV pressure, LV
end-diastolic pressure (LVEDP), heart rate (HR), and LV +dP/
dtmax and LV 2dP/dtmin as measures of ventricular contractility
and relaxation, respectively (Fig. 3).
Lowering Levels of Cardiomyocyte GRK2 Reduces Post-I/
R Myocardial Injury
To determine whether reduced GRK2 levels improve cardiac
function by directly protecting heart against myocardial I/R injury
Figure 3. Loss of Cardiac GRK2 Expression Improves Post-I/R Hemodynamic Function. (A) Representative original LV dP/dt data tracing
acquired from a Sham animal. Data was recorded at baseline (B) and upon isoproterenol treatment (0.1–1.0 ng/mouse). (B–E) Hemodynamic data
(mean6SEM) recorded B and after cumulative doses of isoproterenol administration in Sham control mice (n = 8) and post-I/R groups (MCM, n= 8,
GRK2fl/fl, n = 6, GRK2iKO, n = 9, and GRK2KO, n = 6) at 24 hrs after I/R. Measurements include LV +dP/dtmax (B); LV -dP/dtmin (C); LV end diastolic
pressure (LVEDP (D); and heart rate (HR) (E). *p,0.05 GRK2iKO or GRK2 KO vs. MCM and GRK2fl/fl control groups(two-way ANOVA).
doi:10.1371/journal.pone.0066234.g003
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induced myocyte cell loss we examined post-I/R myocardial
infarct size in our two GRK2 KO mice lines. We dissected hearts
at the end of 24 hrs of reperfusion and used Evan’s Blue/TTC
staining to determine the total LV area at risk (AAR) and infarct
size (expressed as % of AAR). Consistent with the in vivo
functional data, GRK2iKO and GRK2KO mice had significantly
smaller LV infarcts compared to their corresponding control mice
(GRK2iKO, 20.661.3% of AAR vs. MCM, 33.862.9%, p,0.05;
GRK2KO, 22.2961.22% vs. GRK2fl/fl, 33.161.2%, p,0.05)
(Fig. 4A and B). This represents a significant ,35% reduction of
infarct size in hearts with GRK2 is reduced to minimal levels in
myocytes. Importantly, there was no difference in the measured
AAR as a % of the total LV area in any of the mice lines (Fig. 4C).
Cardiac GRK2 KO Reduces Myocardial Apoptosis after
Ischemic Injury
Strong evidence exists showing that myocardial apoptosis is a
major form of cell death following I/R injury. Having demon-
strated that lowering GRK2 significantly reduces infarct size, we
tested whether there were specific changes in myocardial apoptosis
by using TUNEL staining in vivo on cardiac sections and also
determining specific caspase activities assays post- I/R. As shown
in Fig. 5A and 5B, total TUNEL positive nuclei were significantly
reduced in GRK2 KO mice (GRK2iKO, 8.860.5%; GRK2KO,
9.0661.3%) compared to control mice (MCM, 16.360.7%;
GR2fl/fl, 16.660.7%, p,0.05). More importantly, as shown in
Fig. 5C, we found a significant reduction in myocyte-specific
TUNEL labeling when GRK2 was reduced (4.8460.35% in
GRK2iKO mice and 4.9760.72% in GRK2KO mice) compared
to control groups (9.3260.3% in MCM mice and 8.9060.89 in
GRK2fl/fl mice, p,0.05 vs. corresponding GRK2 KO mice).
Moreover, tissue caspase-3 and -9 but not -8 activities were also
significantly decreased in the GRK2 KO lines compared to
control groups after I/R injury (3 hrs) (Fig. 5D–F), suggesting that
lowering GRK2 reduces cardiomyocyte apoptosis through mito-
chondrial-mediated caspase-9 activation (i.e. intrinsic pathway of
apoptotic cell death).
Cardiac GRK2 KO Reduces Mitochondrial Cytochrome C
Release after I/R
To obtain more direct evidence that GRK2 may play a key role
in mitochondrial-dependent apoptosis of myocytes after I/R
injury, we measured cytosolic cytochrome C levels in GRK2
KO and control mice. Cytochrome C is an upstream activator of
caspase-9. This is especially important since we did find caspase-9
activity significantly decreased in both lines of cardiac GRK2 KO
mice post-I/R (Fig. 5E). As shown in Fig. 6A–C, baseline
cytochrome C levels in the cytoplasmic compartment was similar
in all groups (GRK2 KO’s and controls), however, in both
GRK2KO and GRK2iKO mice there was significantly less
cytochrome C released to the cytoplasm after I/R injury (30 min)
compared to controls. After I/R, the level of cytochrome C was
significantly in control mice increased over 300% while GRK2
KO mice had a significant ,50% reduction (Fig.6A–C).
Lowering GRK2 Levels in the Heart Increases Expression
of Anti-apoptotic Bcl-2 Proteins and Activated Anti-
Apoptotic Kinases
To dissect upstream molecular signaling involved in GRK2
activation of the intrinsic apoptosis pathway, several additional
Figure 4. Cardiac GRK2 KO Mice have Reduced Post-I/R Infarct Size. (A) Representative photographs of TTC-stained mouse heart sections
obtained from listed groups 24 hrs after a Sham procedure of I/R injury. (B) Graphic representation of the LV infarct size expressed as percentage of
total ischemic area (Area at risk, AAR) in each group (S, n = 3, MCM, n = 8, GRK2fl/fl, n = 9, GRK2iKO, n = 15, and GRK2KO, n = 8). *p,0.05, vs. MCM and
GRK2fl/fl control mice (ANOVA). (C) Percentage of LV AAR for each group.
doi:10.1371/journal.pone.0066234.g004
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experiments were performed. First, we measured Bcl-2 and Bcl-xL
(anti-apoptotic) protein levels in hearts subjected to a Sham
procedure or I/R injury (30 min of reperfusion). As shown in
Fig. 6D–F, baseline levels of Bcl-2 (E) and Bcl-xL (F) protein were
not changed between GRK2 KO and control mice. After I/R, the
level of Bcl-2 and Bcl-xL were significantly lower in control mice,
however levels of Bcl-2 and Bcl-xL were maintained in GRK2KO
mice indicating significantly more protective Bcl-2 proteins
available after I/R in these mice. These results were essentially
identical in GRK2iKO mice after I/R (Fig. 6G–I). This data
suggests that the anti-apoptotic effect of lowering GRK2 may be at
least partially due to alterations in Bcl-2 signaling, which can
regulate cytochrome C release from mitochondria to activate the
apoptosome [5]. Next, we measured the levels of phosphorylated
Akt (Ser-473), a pro-survival kinase, at baseline (sham conditions)
and 15 min post-I/R where we have found peak myocardial Akt
activation (data not show). As shown in Fig. 7A–B, phosphorylated
(i.e. activated) Akt levels were slightly but significantly elevated in
control GRK2fl/fl mice after I/R injury compared to Sham levels.
However, there was significantly more p-Akt in GRK2KO mice.
This result was mirrored in GRK2iKO mice when compared to
their MCM controls (Fig. 7C–7D).
To validate our in vivo findings of lowered apoptosis after I/R
in GRK2 KO mice, we used a siRNA strategy in neonatal rat
ventricular myocytes (NRVMs) to knock-down GRK2 expression
and then challenged the cells with chelerythrine (chele), an agent
which is known to induce oxidative-stress dependent apoptosis in
myocytes [32,33]. The siRNA treatment decreased GRK2
expression in NRVMs by $50% (Fig. 8A–B). As shown in
Fig. 8A, and 8F, cleaved caspase-3 was significantly increased in
control cells after chele treatment while in cells with lower GRK2
there was significant attenuation of cleaved caspase-3. This
blunted response correlated with increased level of phospho-Akt
(Fig. 8C), and levels of anti-apoptotic Bcl-2 proteins (Fig. 8D–E).
Thus, we found both in vivo and in vitro that myocyte apoptotic
signaling after stress can be limited after decreasing GRK2 levels.
Discussion
In the present study, we directly investigated the mechanistic
role of GRK2 as a pro-death kinase in the heart following ischemic
Figure 5. Cardiac GRK2 KOMice have Reduced Post-I/R Myocardial Apoptosis. (A) Representative photomicrographs of in situ detection of
DNA fragments (TUNEL) in myocardial sections from Sham or post-I/R mice from the listed groups (MCM and GRK2fl/fl as controls as GRK2iKO and
GRK2KO). Total nuclei were labeled with DAPI (blue), and apoptotic nuclei were detected by TUNEL staining (green) and a-actin labeled myocytes in
red. (B,C) Mean6SEM of the percentage of TUNEL positive nuclei per total cell number per field (B) and percentage of TUNEL positive myocytes per
field (C), *p,0.05 vs. MCM and GRK2fl/fl control groups (ANOVA). (D–F) Activity (mean6SEM) of caspase-3 (D), -8 (E), and -9 (F) in all groups with n-
sizes per group listed at bottom of graphs, *p,0.05 vs. MCM and GRK2fl/fl control groups.
doi:10.1371/journal.pone.0066234.g005
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injury. We conducted our studies in two independent lines of
cardiomyocyte-specific GRK2 KO mice (constitutive and induc-
ible) and found that lower GRK2 levels limits acute ischemic
damage after I/R injury. This was manifested by decreased
apoptosis, smaller LV infarcts and improved post2/I/R cardiac
function. These results support recent evidence by our laboratory
showing that overexpression of GRK2 in myocytes enhances
ischemic injury and apoptosis. Our results herein are novel as we
now have shown how the loss of GRK2 expression can be directly
cardioprotective via a significant alteration of pro-survival kinases
and apoptotic molecules. Most importantly, we have shown for the
first time that with lower myocyte GRK2, there is less cytochrome
C release from mitochondria after I/R injury implicating a
mitochondrial-dependent apoptotic process. Indeed, activation of
caspase-9 was lower after I/R in GRK2 KO mice compared to
control mice.
Our data suggests that GRK2 is a nodal regulator of the
apoptotic process after ischemic injury coordinating inhibition of
pro-survival kinases such as Akt and anti-apoptotic Bcl molecules.
Reciprocally, GRK2 promotes cytochrome C release showing that
this kinase is a critical regulator of myocyte death. Having the fact
of pro-apoptosis in myocytes exposed to oxidative stress, it appears
that GRK2 regulates cell death independent of its GRK activity
and this is a novel role for this kinase in the heart. These effects of
GRK2 on myocyte apoptosis appear to be independent of its
GRK activity on GPCRs and support recent data published by us
showing that the pro-death effects of GRK2 in myocytes after
ischemic and oxidative stress are associated with its unique
mitochondrial targeting [33].
Figure 6. Loss of GRK2 in Cardiomyocytes Decreases Cytochrome C Release from Mitochondria after I/R injury and Increases Levels
of the Anti-apoptotic Bcl-2 proteins. (A) Representative Western blot of cytosolic levels of GRK2 and cytochrome C (CytoC) in myocardial lysates
purified from MCM, GRK2fl/fl, GRK2iKO, and GRK2KO mice 30 min after I/R injury. (B) Mean6SEM of CytoC release in MCM and GRK2iKO mice under
Sham conditions and post-I/R with n-sizes shown within the individual bars, *p,0.05 MCM-I/R vs MCM-Sham, #p,0.05 GRK2iKO-I/R vs. MCM-I/R
mice. (C) Mean6SEM of CytoC release in GRK2fl/fl and GRK2KO mice under Sham conditions and post-I/R with n-sizes shown within the individual
bars, *p,0.05 GRK2fl/fl-I/R vs GRK2fl/fl-Sham, #p,0.05 GRK2KO-I/R vs. GRK2fl/fl-I/R mice. (D) Representative Western blot showing GRK2, Bcl-2 and
Bcl-xl protein levels in myocardial lysates purified from Sham or post-I/R GRK2fl/fl control mice or constitutive GRK2KO mice. (E–F) Quantitative levels
(Mean6SEM) of BCL-2 (E) or BCL-xL (F) found in myocardial lysates from Sham or post-I/R GRK2fl/fl control mice or GRK2KO mice, *p,0.05 KO vs
GRK2fl/fl (n = 4 per group). (G) Representative Western blot showing GRK2, Bcl-2 and Bcl-xl protein levels in myocardial lysates purified from Sham or
post-I/R MCM control mice or inducible GRK2iKO mice. (H-I) Quantitative levels (Mean6SEM) of BCL-2 (H) or BCL-xL (I) found in myocardial lysates
from Sham or post-I/R MCM control mice or GRK2iKO mice, *p,0.05 KO vs GRK2fl/fl (n = 4 per group).
doi:10.1371/journal.pone.0066234.g006
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GRK2 is up-regulated in the heart acutely after ischemic stress
[23,34]. In fact, it is one of the earliest adrenergic-associated
molecular changes after cardiac ischemia [23]. GRK2 expression
and activity remains elevated chronically in HF where it promotes
the desensitization and down-regulation of bARs causing the loss
of inotropic reserve [34,35]. This has been thought of as a
protective mechanism to limit receptors in light of enhanced
sympathetic nervous system activity and catecholamine bombard-
ment. However, our data is a direct challenge to this concept as we
have shown that the loss of GRK2 expression in myocytes prior to
any stress or injury offers significant cardioprotection. Moreover,
we have recently shown that the inducible loss of myocyte GRK2
expression after MI–induced HF is already evident, significantly
improves cardiac function with active reverse LV remodeling [22].
Our current results from two different GRK2 KO models
showing cardioprotection after I/R injury support our previous
results where cardiac expression of the GRK2 inhibitory peptide,
bARKct, led to significant cardioprotection and lower myocyte
apoptosis after ischemic injury [25]. Our results are particularly
important since the exact mechanistic target of the bARKct has
been questioned due to it targeting the Gbc-activation of GRK2
[20]. However, since we find the same post-I/R phenotype it is
clear that the bARKct is cardioprotective due to the inhibition of
the pro-death effects of GRK2, which is something we also have
recently found for the mitochondrial-dependent cell death
mechanism and targeting of GRK2 [33,36,37]. Our data now
indicates that the loss of GRK2 acutely blocks a central role that
GRK2 plays in myocyte apoptotic signaling, which appears to be
downstream of oxidative stress and independent from its role as a
GPCR kinase. Indeed, several intracellular kinase cascades were
altered when GRK2 was lowered including the primary pro-
survival kinase, Akt. Interestingly, previous data in liver endothe-
lial cells have shown a direct interaction between increased GRK2
expression and Akt leading to its (Akt’s) inhibition [38]. Although,
we could not confirm a direct interaction in myocytes (data not
shown), our data is consistent with a loss of GRK2 leading directly
to increased Akt activation, at least after ischemic injury. Whether
this is actually a GPCR-dependent process remains to be
addressed. However it is clear that the loss of GRK2 expression
can lead to increased Akt activation after I/R injury and this limits
ischemic injury in the heart.
It is well documented that Akt improves myocardial survival
after I/R injury by inhibiting apoptotic cell death through the
phosphorylation of the death agonist Bcl-xL/Bcl-2–associated
death promoter (BAD) [15]. Phosphorylation of BAD (at Ser136)
by Akt leads to the release of both antiapoptotic Bcl-2 protein Bcl-
xL and Bcl-2 [15,16], which will limit the activation of Bak or Bax,
the pro-apoptotic Bcl-2 proteins. We did test the novel hypothesis
that this can be controlled by GRK2 after I/R injury and this
appears to be the case. Although, we could not detect phosphor-
Figure 7. Activated Akt is Increased in Post-I/R GRK2 KO Hearts. (A) Representative Western blots for GRK2, total Akt and phospho-Akt
(activated via phosphorylation of Ser 473) in myocardial lysates of Sham and post-I/R (30 min I and 15 min R) GRK2fl/fl control mice and constitutive
GRK2KO mice. (B) Quantitative levels (mean6SEM) of phospho-Akt normalized to total Akt found in myocardial lysates from Sham or post-I/R GRK2fl/
fl or GRK2KO mice, *p,0.05 KO vs GRK2fl/fl (n = 4 per group), #p,0.05, GRK2fl/fl-I/R vs. GRK2fl/fl-Sham, **p,0.01, GRK2KO-I/R vs. GRK2fl/fl-I/R and
Sham groups (ANOVA, n = 4 pre group). (C) Representative Western blots for GRK2, total Akt and phospho-Akt in myocardial lysates of Sham and
post-I/R MCM control mice and inducible GRK2KO mice (as in A-B). (D) Quantitative levels (mean6SEM) of phospho-Akt normalized to total Akt found
in myocardial lysates from Sham or post-I/R MCM or GRK2iKO mice, **p,0.01, MCM-IR vs. MCM sham; ##p,0.01, GRK2iKO-I/R vs. MCM-I/R and Sham
groups (ANOVA, n = 4 pre group).
doi:10.1371/journal.pone.0066234.g007
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ylated Bad in our tissue preparation (data not shown), we found
that the total level of Bcl-2 and Bcl-xL were increased after I/R in
GRK2 KO mice compared to control animals. This increase in
the pro-survival Bcl-2 proteins may inhibit the activity of either
Bak or Bax and stabilize the mitochondrial membrane transition
pore (mPTP) and reduce cytochrome C release, which is one of the
novel findings of the study as this mechanism may partially explain
the strong anti-apoptotic effect of lowering GRK2. Moreover, as
detailed above, other recent studies by us show that the pro-death
activity of GRK2 is dependent on its mitochondrial targeting [33]
where Akt and these pro- and anti-apoptotic signaling molecules
can also be localized.
We have found several mechanisms by which GRK2 lowering
might regulate myocyte apoptosis and indicate an unrecognized
importance of this kinase in the injured myocyte. It appears that
GRK2 lies at a nodal point of regulation for multiple cellular
signaling pathways that promotes apoptosis following ischemic
injury and oxidative stress and its loss increases cell survival
through activation of kinase cascades. This includes signaling
mechanisms associated with mitochondria leading to cytochrome
C release that can be significantly attenuated post-I/R by lowering
GRK2 levels. Overall, our results shed new light on how inhibition
or targeting of GRK2 in the heart can be therapeutic including
acutely as a cardioprotective agent after ischemic injury.
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